Completed Brain & Nervous System Cancer
Efficacy, safety and tolerabiilty of minocycline in amyotrophic lateral sclerosis
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by MRC.
View the original record at the funder ↗
Researchers
Ammar Al-Chalabi (Co-Investigator)Christopher Shaw (Co-Investigator)PN Leigh (Principal Investigator)Paul McCrone (Co-Investigator)Stephen Hopkins (Co-Investigator)
Related Research
Grants with similar aims, by meaning.
Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, placebo- controlled, phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Minocycline in Alzheimer's Disease Efficacy Trial: The MADE Trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients
Modulation of immune response and outcomes in ALS using IL-2 (MIROCALS-IL2)
Original classification
Research GrantPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know